ArticleJournal of virology2010
Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex.
Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 141 citations in OpenAlex.
- Degraders of the dengue virus capsid protein exhibit differentiated pharmacology relative to capsid inhibitors.Nature communications · 2026Article
- Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026Review
- CpG oligodeoxynucleotides and pan-serotype inhibitors control neurotropic dengue infection in novel immune competent neonatal mouse model.Emerging microbes & infections · 2025Article
- Early events in dengue virus infection inducing cytokine storm: The dynamic interplay of pattern-recognition receptors, inflammasome activation, and biphasic NF-κB and STAT1-dependent inflammatory responses in human mononuclear phagocytes.PLoS neglected tropical diseases · 2025Article
- Conventional and antibody-enhanced DENV infection of human macrophages induces differential immunotranscriptomic profiles.Journal of virology · 2025Article
- Double-stranded RNA orbivirus disrupts the DNA-sensing cGAS-sting axis to prevent type I IFN induction.Cellular and molecular life sciences : CMLS · 2025Article
- From viruses to cancer: exploring the role of the hepatitis C virus NS3 protein in carcinogenesis.Infectious agents and cancer · 2024Review
- Elevated NS1 serum levels reduce CD119 expression and CXCL-10 synthesis in patients with dengue hemorrhagic fever.Revista da Sociedade Brasileira de Medicina Tropical · 2024Article
- Lambda-free light chain: A serum marker of dengue disease via NS3 protease-mediated antibody cleavage.Virulence · 2023Article
- Mosquito-borne flaviviruses and type I interferon: catch me if you can!Frontiers in microbiology · 2023Review
- The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- Dengue virus co-opts innate type 2 pathways to escape early control of viral replication.Communications biology · 2022Article
- Generation and Characterization of Human-Mouse STING Chimeras That Allow DENV Replication in Mouse Cells.mSphere · 2022Article
- Lineage Replacement Associated with Fitness Gain in Mammalian Cells andMicroorganisms · 2022Article
- Japanese Encephalitis Virus NS2B-3 Protein Complex Promotes Cell Apoptosis and Viral Particle Release by Down-Regulating the Expression of AXL.Virologica Sinica · 2021Article
- Review
- Article
- TAP dysfunction in dendritic cells enables noncanonical cross-presentation for T cell priming.Nature immunology · 2021Article
- Recent Insights Into the Molecular Mechanism of Toll-Like Receptor Response to Dengue Virus Infection.Frontiers in microbiology · 2021Review
- Tree Shrew as a New Animal Model for the Study of Dengue Virus.Frontiers in immunology · 2021Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Dengue virus (DENV) is the most prevalent arthropod-borne human virus, able to infect and replicate in human dendritic cells (DCs), inducing their activation and the production of proinflammatory cytokines. However, DENV can successfully evade the immune response in order to produce disease in humans. Several mechanisms of immune evasion have been suggested for DENV, most of them involving interference with type I interferon (IFN) signaling. We recently reported that DENV infection of human DCs does not induce type I IFN production by those infected DCs, impairing their ability to prime naive T cells toward Th1 immunity. In this article, we report that DENV also reduces the ability of DCs to produce type I IFN in response to several inducers, such as infection with other viruses or exposure to Toll-like receptor (TLR) ligands, indicating that DENV antagonizes the type I IFN production pathway in human DCs. DENV-infected human DCs showed a reduced type I IFN response to Newcastle disease virus (NDV), Sendai virus (SeV), and Semliki Forest virus (SFV) infection and to the TLR3 agonist poly(I:C). This inhibitory effect is DENV dose dependent, requires DENV replication, and takes place in DENV-infected DCs as early as 2 h after infection. Expressing individual proteins of DENV in the presence of an IFN-alpha/beta production inducer reveals that a catalytically active viral protease complex is required to reduce type I IFN production significantly. These results provide a new mechanism by which DENV evades the immune system in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.